$290.71
+3.12 (+1.08%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where LGND is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
21 interventional · 2 with posted results
Held by 6 tracked-famous managers (D. E. Shaw & Co., Inc., Squarepoint Ops LLC, TWO SIGMA INVESTMENTS, LP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, AQR CAPITAL MANAGEMENT LLC, +1 more) · FINRA short interest 7.4 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 16 sells · government filings 180d: 2 congress / 0 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary AngiographyNCT04627831Incidence of contrast-induced acute kidney injury (CI-AKI)Randomized · Quadruple-masked · Prevention | Phase 2 | Withdrawnsponsor's stated reason: Internal decision | Drug: CE-Iohexol, Iohexol | Contrast-induced Nephropathy | 0 | Mar 2023 | 2022-04-11 |
| A Study of LGD-6972 in Patients With Type 2 Diabetes MellitusNCT02851849Change from baseline in HbA1cRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: LGD-6972-5 mg, LGD-6972-10 mg, LGD-6972-15 mg · Other: Placebo | Type 2 Diabetes Mellitus | 148 | Jun 2017actual | 2018-01-12 |
| A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution FormulationNCT02672839Pharmacokinetics Analysis- Area Under the Concentration Curve (AUC)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: LGD-6972 Solution, LGD-6972 Capsules | Type 2 Diabetes Mellitus (T2DM) | 12 | May 2016actual | 2016-05-18 |
| Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes MellitusNCT02250222Number of participants with one or more drug related adverse events or serious adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: LGD-6972, Placebo (Captisol ®) | Type 2 Diabetes Mellitus | 48 | May 2015actual | 2015-06-11 |
| Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes MellitusNCT01919684Safety and tolerability of single oral doses of LGD-6972 in healthy subjects and in subjects with T2DM.Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: LGD-6972, Placebo (Captisol®) | Type 2 Diabetes Mellitus | 56 | Feb 2014actual | 2014-09-25 |
| Study of MB07811 in Subjects With HypercholesterolemiaNCT00879112Evaluate the effects of MB07811 compared to placebo on LDL-CRandomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Study terminated prior to initiation | Drug: MB07811, Placebo | Hypercholesterolemia | 80 | Dec 2009 | 2011-08-12 |
| A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With HypertensionNCT00635232results2011-09-13Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) Following 12 Weeks of Treatment With PS433540 200 mg, 400 mg, 800 mg and Placebo.Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: irbesartan, placebo, PS433540, PS433540, PS433540 | Hypertension | 261 | Nov 2008actual | 2011-09-16 |
| The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs SyndromeNCT00626418To assess the efficacy and tolerability of single doses of aplindore compared to placebo in RLS.Randomized · Single-masked · Treatment | Phase 2 | Completed | Drug: Aplindore, Placebo | Restless Legs Syndrome | 24 | Oct 2008actual | 2011-10-03 |
| The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's DiseaseNCT00623324Evaluation of safety and tolerability dataRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Aplindore, Placebo | Early Stage Parkinson's Disease | 40 | Jul 2008actual | 2011-10-03 |
| Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic RhinitisNCT00940953Patient-rated Total Nasal Symptom ScoreRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Budesonide + Azelastine, Budesonide + Azelastine, Placebo | Seasonal Allergic Rhinitis | 108 | May 2008actual | 2012-10-04 |
| A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat HypertensionNCT00522925results2011-09-14Change From Baseline in Mean 24-hour Ambulatory Systolic Blood PressureRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: PS433540, placebo, PS433540 | Hypertension | 280 | Apr 2008actual | 2011-09-16 |
| Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes MellitusNCT00458016Fasting Plasma Glucose ConcentrationRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: MB07803, Placebo | Type 2 Diabetes Mellitus | 105 | Mar 2008actual | 2011-10-03 |
| Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)NCT00141323New morphometric vertebral fracturesRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: lasofoxifene, lasofoxifene · Other: placebo | Osteoporosis | 8,556 | Dec 2007actual | 2011-08-15 |
| Safety and Tolerability of I.V. Infusion of MB07133 in Patients With Unresectable Hepatocellular CarcinomaNCT00073736Safety and tolerabilityNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: MB07133 300mg/m2/day, MB07133 600 mg/m2/day, MB07133 1200 mg/m2/day, MB07133 1800 mg/m2/day, MB07133 2400 mg/m2/day | Hepatocellular Carcinoma | 28 | Jul 2007actual | 2011-08-12 |
| Compare CE-Budesonide Nasal Solution & Rhinocort Aqua in an EEC Study of ARNCT00938613Total Nasal Symptom ScoreRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Budesonide, Placebo, Budesonide | Seasonal Allergic Rhinitis | 65 | Apr 2007actual | 2012-10-04 |
| Dose Response Study of Lasofoxifene in Postmenopausal Women With Osteoporosis - Japanese Asian Dose EvaluationNCT00143273Effects of lasofoxifene compared to placebo on Bone Mineral Density (BMD) changes at the spine and hip after 1 year of treatmentRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: lasofoxifene, Placebo, Lasofoxifene, Lasofoxifene | Osteoporosis | 497 | Mar 2006actual | 2011-08-10 |
| Comparison of Raloxifene and Lasofoxifene - A Randomized, Blinded Study of These Drugs and Placebo on Bone LossNCT00163137Spine BMD after 2 yearsRandomized · Quadruple-masked · Prevention | Phase 3 | Completed | Drug: lasofoxifene, raloxifene, Placebo | Osteoporosis | 540 | Oct 2005actual | 2011-08-12 |
| A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's SarcomaNCT00002212Treatment | Phase 2 | Completed | Drug: Bexarotene | Sarcoma, Kaposi, HIV Infections | 27 | — | 2005-06-24 |
| Bexarotene in Treating Patients With Metastatic Breast CancerNCT00003752Randomized · Treatment | Phase 2 | Completed | Drug: bexarotene | Breast Cancer | 180 | — | 2013-05-30 |
| Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell LymphomaNCT00006345Supportive care | Phase 2 | Completed | Biological: denileukin diftitox · Drug: dexamethasone | Drug/Agent Toxicity by Tissue/Organ, Lymphoma | — | — | 2013-05-30 |
| The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine EvaluationNCT00674453Change in bone mineral density of the lumbar spine.Randomized · Quadruple-masked · Basic science | Phase 2 | Completed | Drug: Lasofoxifene · Other: Placebo | Bone Loss | 51 | — | 2011-08-10 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19